The estimated Net Worth of James Huang is at least $1.4 Millón dollars as of 6 September 2022. Mr. Huang owns over 55,573 units of Windtree Therapeutics stock worth over $1,133,127 and over the last 10 years he sold WINT stock worth over $0. In addition, he makes $271,478 as Independent Chairman of the Board at Windtree Therapeutics.
Sign up
Mr. Huang WINT stock SEC Form 4 insiders trading
James has made over 16 trades of the Windtree Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 55,573 units of WINT stock worth $229,516 on 6 September 2022.
The largest trade he's ever made was buying 1,655,629 units of Windtree Therapeutics stock on 6 December 2019 worth over $5,000,000. On average, James trades about 77,641 units every 30 days since 2014. As of 6 September 2022 he still owns at least 371,517 units of Windtree Therapeutics stock.
You can see the complete history of Mr. Huang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Huang biography
James Z. Huang serves as Independent Chairman of the Board of the Company. Mr. Huang is a founding and Managing Partner to Panacea Venture. Panacea Venture is a venture capital firm that invests in early and growth stage healthcare and life sciences companies worldwide. Since 2011, Mr. Huang has served as a Managing Partner of Kleiner Perkins Caufield & Byers, or KPCB - China, an investment advisory firm, focusing on the firm’s life sciences practice. Mr. Huang has made more than 15 investments in China since 2007. Prior to joining KPCB China, Mr. Huang was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. Prior to joining Vivo in 2007, Mr. Huang was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, Mr. Huang also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (subsequently acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (subsequently acquired by Johnson & Johnson). Mr. Huang is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at ChiralQuest, Zenesis, and CASI Pharmaceuticals. Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
What is the salary of James Huang?
As the Independent Chairman of the Board of Windtree Therapeutics, the total compensation of James Huang at Windtree Therapeutics is $271,478. There are 6 executives at Windtree Therapeutics getting paid more, with Craig Fraser having the highest compensation of $1,063,640.
How old is James Huang?
James Huang is 55, he's been the Independent Chairman of the Board of Windtree Therapeutics since 2018. There are 12 older and 3 younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
What's James Huang's mailing address?
James's mailing address filed with the SEC is C/O WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Insiders trading at Windtree Therapeutics
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... y Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
What does Windtree Therapeutics do?
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
What does Windtree Therapeutics's logo look like?
Complete history of Mr. Huang stock trades at CASI Pharmaceuticals Inc, Alaunos Therapeutics Inc y Windtree Therapeutics
Windtree Therapeutics executives and stock owners
Windtree Therapeutics executives and other stock owners filed with the SEC include:
-
Craig Fraser,
President, Chief Executive Officer, Director -
Craig E. Fraser,
Pres, CEO & Director -
Steven Simonson,
Senior Vice President and Chief Medical Officer -
Eric L. Curtis M.B.A.,
Sr. VP & COO -
John P. Hamill,
Sr. VP, CFO & Corp. Sec. -
Mary Templeton,
Senior Vice President, General Counsel and Corporate Secretary -
James Huang,
Independent Chairman of the Board -
Brian Schreiber,
Independent Director -
Bruce Peacock,
Independent Director -
Joseph Mahady,
Independent Director -
John Leone,
Independent Director -
Daniel Geffken,
Independent Director -
Pratap Paruchuru,
Executive Director of Clinical Development -
Eric Curtis,
Chief Operating Officer, Senior Vice President -
John Hamill,
Chief Financial Officer, Senior Vice President -
Dr. Steven G. Simonson,
Sr. VP & Chief Medical Officer -
Diane Carman Esq.,
Sr. VP & Gen. Counsel -
Dr. Ronald L. Dundore,
Exec. Director of Regulatory Affairs & Quality -
Tracy Rarick,
Head of Operations & Program Management -
George Cox,
VP of Technical Operations -
Diane Carman,
SVP & General Counsel -
Leslie J. Williams,
Director -
Evan Loh,
Director -
Ii Investments Ltd Lph,
10% owner -
Pharmaceutical Holdings Ltd...,
10% owner -
John A Tattory,
SVP & CFO -
Mark Strobeck,
Director -
Capital Inc. Bioengine,
10% owner -
Laboratories, Inc. Center,
10% owner -
Robert A Scott,
Director